Research & Literature

Latent and Active Tuberculosis Infection Increase Immune Activation in Individuals Co-Infected with HIV.

Sullivan ZA, Wong EB, Ndung'u T, et al.

EBioMedicine 2015; (2(4)):334-340 doi:10.1016/j.ebiom.2015.03.005.

Pulmonary aspergillosis presenting with recurrent haemoptysis.

Betancourt BY, Garofoli AC, Sandhu JS, et al.

BMJ case reports 2015; (2015()).

Incidence and prognostic factor of ethambutol-related optic neuropathy: 10-year experience in southern Taiwan.

Chen SC, Lin MC, Sheu SJ

The Kaohsiung journal of medical sciences 2015; (31(7)):358-62.

Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.

Bliven-Sizemore EE, Sterling TR, Shang N, et al.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2015; (19(9)):1039-44, i-v doi:10.5588/ijtld.14.0829.

Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.

Gray EL, Goldberg HF

Internal medicine journal 2016; (46(3)):281-7 doi:10.1111/imj.12979.

Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

Fujita K, Terashima T, Mio T

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016; (11(12)):2238-2240 doi:10.1016/j.jtho.2016.07.006.

Rifapentine for the treatment of latent tuberculosis.

Egelund EF, Peloquin CA

Expert review of clinical pharmacology 2016; (9(10)):1253-1261 doi:10.1080/17512433.2016.1222270.

Relation between BCG vaccine scar and an interferon-gamma release assay in immigrant children with "positive" tuberculin skin test (≥10 mm).

Gudjónsdóttir MJ, Kötz K, Nielsen RS, et al.

BMC infectious diseases 2016; (16(1)):540 doi:10.1186/s12879-016-1872-9.

Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis.

Johnston JC, Campbell JR, Menzies D

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017; (64(9)):1211-1220 doi:10.1093/cid/cix121.

Primary intimal sarcoma of the left atrium presenting with constitutional symptoms.

Marques Mendes E, Ferreira A, Felgueiras P, et al.

Oxford medical case reports 2017; (2017(7)):omx031 doi:10.1093/omcr/omx031.

Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study.

Bahr NC, Nuwagira E, Evans EE, et al.

The Lancet. Infectious diseases 2018; (18(1)):68-75 doi:10.1016/S1473-3099(17)30474-7.

Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis.

Lv L, Li T, Xu K, et al.

Infection and drug resistance 2018; (11()):147-154 doi:10.2147/IDR.S153499.

Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.

Njie GJ, Morris SB, Woodruff RY, et al.

American journal of preventive medicine 2018; (55(2)):244-252 doi:10.1016/j.amepre.2018.04.030.

Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.

Sun HY, Huang YW, Huang WC, et al.

Tuberculosis (Edinburgh, Scotland) 2018; (111()):121-126 doi:10.1016/j.tube.2018.05.013.

Alveolar Macrophages Provide an Early Mycobacterium tuberculosis Niche and Initiate Dissemination.

Cohen SB, Gern BH, Delahaye JL, et al.

Cell host & microbe 2018; (24(3)):439-446.e4 doi:10.1016/j.chom.2018.08.001.

Host resistance to pulmonary Mycobacterium tuberculosis infection requires CD153 expression.

Sallin MA, Kauffman KD, Riou C, et al.

Nature microbiology 2018; (3(11)):1198-1205 doi:10.1038/s41564-018-0231-6.

Anatomic and Cellular Niches for Mycobacterium tuberculosis in Latent Tuberculosis Infection.

Mayito J, Andia I, Belay M, et al.

The Journal of infectious diseases 2019; (219(5)):685-694 doi:10.1093/infdis/jiy579.

Latent tuberculosis infection and non-infectious co-morbidities: Diabetes mellitus type 2, chronic kidney disease and rheumatoid arthritis.

Ugarte-Gil C, Carrillo-Larco RM, Kirwan DE

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2019; (80S()):S29-S31 doi:10.1016/j.ijid.2019.02.018.

Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014.

Wheeler C, Mohle-Boetani J

Public health reports (Washington, D.C. : 1974) 2019; (134(1_suppl)):71S-79S doi:10.1177/0033354919826557.

Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI.

Lee MR, Huang HL, Lin SW, et al.

Journal of clinical medicine 2019; (8(6)) doi:10.3390/jcm8060812.

A healthy patient with positive mantoux test but negative quantiferon Gold assay and no evidence of risk factors - to treat or not to treat?

Montane Jaime LK, Akpaka PE, Vuma S, Justiz-Vaillant AA

IDCases 2019; (18()):e00658 doi:10.1016/j.idcr.2019.e00658.

Treatment of Drug-Susceptible Tuberculosis.

Zha BS, Nahid P

Clinics in chest medicine 2019; (40(4)):763-774 doi:10.1016/j.ccm.2019.07.006.

Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs.

Ronald LA, FitzGerald JM, Bartlett-Esquilant G, et al.

The European respiratory journal 2020; (55(3)) doi:10.1183/13993003.02048-2019.

The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.

Mpobela Agnarson A, Williams A, Kambili C, et al.

Expert review of anti-infective therapy 2020; (18(5)):475-483 doi:10.1080/14787210.2020.1742109.

Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.

Dooley KE, Savic R, Gupte A, et al.

The lancet. HIV 2020; (7(6)):e401-e409 doi:10.1016/S2352-3018(20)30032-1.

Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.

Puig L, Tsai TF, Bhutani T, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2020; (34(8)):1744-1749 doi:10.1111/jdv.16460.

Incidence and predictors of extrapulmonary tuberculosis among people living with Human Immunodeficiency Virus in Addis Ababa, Ethiopia: A retrospective cohort study.

Alemu A, Yesuf A, Gebrehanna E, et al.

PloS one 2020; (15(5)):e0232426 doi:10.1371/journal.pone.0232426.

Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.

Bastos ML, Campbell JR, Oxlade O, et al.

Annals of internal medicine 2020; (173(3)):169-178 doi:10.7326/M19-3741.

Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study.

Feleke BE, Feleke TE, Adane WG, Girma A

Virology journal 2020; (17(1)):113 doi:10.1186/s12985-020-01385-z.

Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers Association.

Cole B, Nilsen DM, Will L, et al.

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports 2020; (69(7)):1-27 doi:10.15585/mmwr.rr6907a1.

The epidemiology of extrapulmonary tuberculosis in China: A large-scale multi-center observational study.

Kang W, Yu J, Du J, et al.

PloS one 2020; (15(8)):e0237753 doi:10.1371/journal.pone.0237753.

Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.

Huang HL, Lee MR, Cheng MH, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (73(5)):e1064-e1071 doi:10.1093/cid/ciaa1741.

Epidemiology and the diagnostic challenge of extra-pulmonary tuberculosis in a teaching hospital in Ethiopia.

Arega B, Mersha A, Minda A, et al.

PloS one 2020; (15(12)):e0243945 doi:10.1371/journal.pone.0243945.

Behçet's disease with latent Mycobacterium tuberculosis infection.

Shen Y, Ma H, Luo D, et al.

Open medicine (Warsaw, Poland) 2021; (16(1)):14-22 doi:10.1515/med-2021-0002.

Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia.

Molla Y, Wubetu M, Dessie B

Hepatic medicine : evidence and research 2021; (13()):1-8 doi:10.2147/HMER.S290542.

Comparing the impact of genotypic based diagnostic algorithm on time to treatment initiation and treatment outcomes among drug-resistant tuberculosis patients in Amhara region, Ethiopia.

Kassa GM, Merid MW, Muluneh AG, Wolde HF

PloS one 2021; (16(2)):e0246938 doi:10.1371/journal.pone.0246938.

Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.

Roelens M, Battista Migliori G, Rozanova L, et al.

American journal of respiratory and critical care medicine 2021; (204(6)):713-722 doi:10.1164/rccm.202009-3527OC.

Pulmonary Tuberculosis With Saddle Pulmonary Embolism and Deep Vein Thrombosis: A Rare Case Report.

Subahi EA, Alawad MJ, Abdelmahmuod EA, et al.

Cureus 2021; (13(6)):e15958 doi:10.7759/cureus.15958.

Tracing TB: Are there predictors for active TB disease in patients with Xpert Ultra trace results?

Dowling WB, Whitelaw A, Nel P

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2022; (114()):115-123 doi:10.1016/j.ijid.2021.10.056.

Risk factors associated with drug-resistant tuberculosis in Ethiopia: A systematic review and meta-analysis.

Alemu A, Bitew ZW, Diriba G, Gumi B

Transboundary and emerging diseases 2022; (69(5)):2559-2572 doi:10.1111/tbed.14378.

Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.

Tseng SY, Huang YS, Chang TE, et al.

Journal of the Chinese Medical Association : JCMA 2021; (84(11)):993-1000 doi:10.1097/JCMA.0000000000000605.

The pipeline of new molecules and regimens against drug-resistant tuberculosis.

Black TA, Buchwald UK

Journal of clinical tuberculosis and other mycobacterial diseases 2021; (25()):100285 doi:10.1016/j.jctube.2021.100285.

Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy.

Saxena R, Singh D, Phuljhele S, et al.

Indian journal of ophthalmology 2021; (69(12)):3734-3739 doi:10.4103/ijo.IJO_3746_20.

The definition of tuberculosis infection based on the spectrum of tuberculosis disease.

Migliori GB, Ong CWM, Petrone L, et al.

Breathe (Sheffield, England) 2021; (17(3)):210079 doi:10.1183/20734735.0079-2021.

Co-existing active pulmonary tuberculosis with aspergilloma in a diabetic patient: A rare case report.

Soewondo W, Kusumaningrum CS, Hanafi M, et al.

Radiology case reports 2022; (17(4)):1136-1142 doi:10.1016/j.radcr.2021.12.064.

Culturally adapted pulmonary rehabilitation for adults living with post-tuberculosis lung disease in Kyrgyzstan: protocol for a randomised controlled trial with blinded outcome measures.

Akylbekov A, Orme MW, Jones AV, et al.

BMJ open 2022; (12(2)):e048664 doi:10.1136/bmjopen-2021-048664.

Effectiveness and Safety of Short-term Regimen for Multidrug-resistant Tuberculosis Treatment: A Systematic Review of Cohort Studies.

Mahardani PN, Wati DK, Siloam A, et al.

Oman medical journal 2022; (37(1)):e337 doi:10.5001/omj.2021.64.

Drug resistant TB - latest developments in epidemiology, diagnostics and management.

Tiberi S, Utjesanovic N, Galvin J, et al.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2022; (124 Suppl 1()):S20-S25 doi:10.1016/j.ijid.2022.03.026.

Rasmussen's Aneurysm: A Rare Case.

Jadhav SS, Dhok A, Chaudhari SV, et al.

Cureus 2022; (14(6)):e25740 doi:10.7759/cureus.25740.

Incidence and outcomes of adverse drug reactions to first-line anti-tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study.

Choi H, Park HA, Hyun IG, et al.

Pharmacoepidemiology and drug safety 2022; (31(11)):1153-1163 doi:10.1002/pds.5513.

Prevalence of proximate risk factors of active tuberculosis in latent tuberculosis infection: A cross-sectional study from South India.

Munisankar S, Rajamanickam A, Balasubramanian S, et al.

Frontiers in public health 2022; (10()):1011388 doi:10.3389/fpubh.2022.1011388.

Update on drug treatments for multidrug resistant tuberculosis.

Davies GR, Aston S

Current opinion in infectious diseases 2023; (36(2)):132-139 doi:10.1097/QCO.0000000000000899.

Update of drug-resistant tuberculosis treatment guidelines: A turning point.

Vanino E, Granozzi B, Akkerman OW, et al.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023; (130 Suppl 1()):S12-S15 doi:10.1016/j.ijid.2023.03.013.

Magnitude and factors associated with post-tuberculosis lung disease in low- and middle-income countries: A systematic review and meta-analysis.

Maleche-Obimbo E, Odhiambo MA, Njeri L, et al.

PLOS global public health 2022; (2(12)):e0000805 doi:10.1371/journal.pgph.0000805.

Post-TB health and wellbeing.

Nightingale R, Carlin F, Meghji J, et al.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2023; (27(4)):248-283 doi:10.5588/ijtld.22.0514.

Burden of Mycobacterium tuberculosis and Associated Factors among Presumptive Extra pulmonary Tuberculosis Patients from Selected Health Facilities, Addis Ababa, Ethiopia.

Alehegn E, Gebreyohanns A, Berhane B, et al.

IJID regions 2023; (7()):199-205 doi:10.1016/j.ijregi.2023.03.007.

Diagnosis of extrapulmonary tuberculosis by GeneXpert MTB/RIF Ultra assay.

Dahiya B, Mehta N, Soni A, Mehta PK

Expert review of molecular diagnostics 2023; (23(7)):561-582 doi:10.1080/14737159.2023.2223980.

Diabetes mellitus and latent tuberculosis infection: an updated meta-analysis and systematic review.

Zhou G, Guo X, Cai S, et al.

BMC infectious diseases 2023; (23(1)):770 doi:10.1186/s12879-023-08775-y.

The significance of persisters in tuberculosis drug discovery: Exploring the potential of targeting the glyoxylate shunt pathway.

Negi A, Sharma R

European journal of medicinal chemistry 2024; (265()):116058 doi:10.1016/j.ejmech.2023.116058.

Screening for post-TB lung disease at TB treatment completion: Are symptoms sufficient?

Meghji J, Gunsaru V, Chinoko B, et al.

PLOS global public health 2024; (4(1)):e0002659 doi:10.1371/journal.pgph.0002659.

Ethambutol and its ophthalmic effects; is screening and collaboration the new way forward?

Vyas A, Subramanyam A, Phatak S, Tiwari S

The Indian journal of tuberculosis 2024; (71(1)):30-34 doi:10.1016/j.ijtb.2023.03.009.

Chronic cavitary pulmonary aspergillosis as a sequela of pulmonary tuberculosis: A case report from Pakistan.

Uzair A, Waseem M, Bhatti NI, et al.

SAGE open medical case reports 2024; (12()):2050313X241251777 doi:10.1177/2050313X241251777.

Evaluation of time to sputum smear conversion and its association with treatment outcomes among drug-resistant tuberculosis patients: a retrospective record-reviewing study.

Alzarea AI, Saifullah A, Khan YH, et al.

Frontiers in pharmacology 2024; (15()):1370344 doi:10.3389/fphar.2024.1370344.

A time-to-event modelling of sputum conversion within two months after antituberculosis initiation among drug-susceptible smear positive pulmonary tuberculosis patients: Implementation of internal and external validation.

Muda MR, Albitar O, Harun SN, et al.

Tuberculosis (Edinburgh, Scotland) 2024; (148()):102553 doi:10.1016/j.tube.2024.102553.

Late diagnosis of disseminated tuberculosis: A case report.

Rodriguez-Hidalgo LA, Ruíz Caballero DC, Vega-Fernandez A

Medwave 2024; (24(7)):e2917 doi:10.5867/medwave.2024.07.2917.

Assessing Infectiousness and the Impact of Effective Treatment to Guide Isolation Recommendations for People With Pulmonary Tuberculosis.

Nathavitharana RR, Pearl A, Biewer A, et al.

The Journal of infectious diseases 2025; (231(1)):10-22 doi:10.1093/infdis/jiae482.

Investigation of the prevalence of latent tuberculosis in cancer patients compared to non-cancer patients: a case-control study.

Mortezazadeh M, Karimi M, Esfandbod M, et al.

Oncology reviews 2024; (18()):1445678 doi:10.3389/or.2024.1445678.

Diagnostic accuracy of Xpert MTB/RIF Ultra for detecting pulmonary tuberculosis and rifampicin resistance: a systematic review and meta-analysis.

Wang MQ, Zheng YF, Hu YQ, et al.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2025; (44(3)):681-702 doi:10.1007/s10096-024-05032-1.

Prospective evaluation of ethambutol toxic optic neuropathy in patients of pulmonary tuberculosis.

Sharma N, Gahlot A, Goyal JL, et al.

The Indian journal of tuberculosis 2025; (72(1)):69-73 doi:10.1016/j.ijtb.2023.11.001.

Timing matters in macrophage/CD4+ T cell interactions: an agent-based model comparing Mycobacterium tuberculosis host-pathogen interactions between latently infected and naïve individuals.

Hoerter A, Petrucciani A, Bonifacio J, et al.

mSystems 2025; (10(3)):e0129024 doi:10.1128/msystems.01290-24.

The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan.

Sinha A, Klebe R, Rekart ML, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2025; (81(4)):838-845 doi:10.1093/cid/ciaf035.

Evaluation and Comparison of Laboratory Methods in Diagnosing Mycobacterium tuberculosis and Nontuberculous Mycobacteria in 3012 Sputum Samples.

Wu Q, Zhu Y, Zhang Y, et al.

The clinical respiratory journal 2025; (19(3)):e70071 doi:10.1111/crj.70071.

CD4 T cell dysfunction is associated with bacterial recrudescence during chronic tuberculosis.

Chang E, Cavallo K, Behar SM

Nature communications 2025; (16(1)):2636 doi:10.1038/s41467-025-57819-1.

Adverse events of tuberculosis preventive therapy among individuals with latent tuberculosis infection: A nationwide cohort study in South Korea.

Oh SH, Lee J, Jo J, Kwon JW

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2025; (156()):107914 doi:10.1016/j.ijid.2025.107914.

Prevalence and Incidence of Ethambutol-Induced Optic Neuropathy and Its Risk Factors in Korea: A Nationwide Population-Based Study.

Lee S, Ryu WY, Kang D, Lee JK

Journal of Korean medical science 2025; (40(20)):e65 doi:10.3346/jkms.2025.40.e65.

Clinical profile and visual outcomes in ethambutol-induced toxic optic neuropathy.

Sheth J, Sachdeva V, Goyal A, et al.

Indian journal of ophthalmology 2025; (73(Suppl 3)):S484-S491 doi:10.4103/IJO.IJO_1807_24.

Correlation of Trace detection in Gene Xpert MTB/RIF ultra with MGIT TB culture in a high TB-endemic Country.

Naik S, Dhaneja S, Khilari A, et al.

Tuberculosis (Edinburgh, Scotland) 2025; (154()):102666 doi:10.1016/j.tube.2025.102666.

Progression of tuberculosis among patients with rheumatic diseases - A systematic review and meta-analysis.

Sundaram K, Vajravelu LK, Velayutham R, Mohan U

The Indian journal of tuberculosis 2025; (72(2)):174-182 doi:10.1016/j.ijtb.2023.07.001.

Effectiveness of pulmonary rehabilitation on functional exercise capacity & health related quality of life (HRQOL) among individuals with post tuberculosis lung disease: A multicentric pre & post-interventional study.

Sinha S, Titiyal R, Mounika P, et al.

The Indian journal of medical research 2025; (161(5)):540-551.

Assessment of Clinical, Histopathologic, and Radiologic Features in Extrapulmonary Tuberculosis Patients.

Kharraz L, Bagheri A, Hatami F, et al.

Tanaffos 2024; (23(4)):349-354.

Effectiveness and safety of the BPaL regimen in the Philippines.

Flores I, Quelapio MI, Cabalitan C, et al.

Journal of clinical tuberculosis and other mycobacterial diseases 2025; (41()):100567 doi:10.1016/j.jctube.2025.100567.

Lower Lobe, Higher Suspicion: An Atypical Presentation of Pulmonary Tuberculosis.

Diaz O, Habib D, Naranjo Valle HD, et al.

Cureus 2025; (17(10)):e93783 doi:10.7759/cureus.93783.

Incidence and risk factors of abnormal liver function and anti-tuberculosis drug-induced liver injury: a multicenter retrospective study involving 482 chinese pediatric tuberculosis patients.

Zhou Y, Wang M, Xu H, et al.

Annals of medicine 2025; (57(1)):2546701 doi:10.1080/07853890.2025.2546701.

Comparison of Interferon-Gamma Release Assay and Tuberculin Skin Test in Screening for Latent Tuberculous Infection Among Students from High-Burden Areas: A Prospective Head-to-Head Study in Qingdao, China.

Wang Z, Zhang K, Sun H, et al.

Tropical medicine and infectious disease 2025; (10(11)) doi:10.3390/tropicalmed10110311.

Analysis of factors influencing plasma concentrations of anti-TB drugs in pediatric TB patients.

Huang Y, Guo Q, Wen Y, et al.

BMC infectious diseases 2025; doi:10.1186/s12879-025-12247-w.

Evaluation of Xpert MTB/Rif Versus Mycobacterium Growth Indicator Tube 960 for Rifampicin Resistance Detection in Extrapulmonary Isolates.

Pongiyannan L, Nair D, Gupta NK

International journal of mycobacteriology 2025; (14(4)):370-374 doi:10.4103/ijmy.ijmy_169_25.

Estimation of second line anti-tubercular drug susceptibility to Mycobacterium tuberculosis in clinical isolates.

Sudersanan H, Ravikumar NM, Mishra B

Iranian journal of microbiology 2025; (17(6)):936-941 doi:10.18502/ijm.v17i6.20361.

Latent Tuberculosis Infection among Household Contacts of Drug-sensitive Pulmonary Tuberculosis Patients: A Cross-sectional Study from Medan, Indonesia.

Sinaga BYM, Siregar J, Sormin DE, et al.

Acta medica Philippina 2025; (59(19)):84-90 doi:10.47895/amp.vi0.10048.

Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China.

Fu L, Shi H, Sun F, et al.

BMC infectious diseases 2026; (26(1)).